...
首页> 外文期刊>Molecular pharmaceutics >Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer
【24h】

Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer

机译:基于siRNA介导的DJ-1蛋白抑制机制的铂耐药卵巢癌机制性纳米治疗方法。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We report an efficient therapeutic modality for platinum resistant ovarian cancer based on siRNA-mediated suppression of a multifunctional DJ-1 protein that is responsible for the proliferation, growth, invasion, oxidative stress, and overall survival of various cancers. The developed therapeutic strategy can work alone or in concert with a low dose of the first line chemotherapeutic agent cisplatin, to elicit a maximal therapeutic response. To achieve an efficient DJ-1 knockdown, we constructed the polypropylenimine dendrimer-based nanoplatform targeted to LHRH receptors overexpressed on ovarian cancer cells. The quantitative PCR and Western immunoblotting analysis revealed that the delivered DJ-1 siRNA downregulated the expression of targeted mRNA and corresponding protein by more than 80% in various ovarian cancer cells. It was further demonstrated that siRNA-mediated DJ-1 suppression dramatically impaired proliferation, viability, and migration of the employed ovarian cancer cells. Finally, the combinatorial approach led to the most pronounced therapeutic response in all the studied cell lines, outperforming both siRNA-mediated DJ-1 knockdown and cisplatin treatment alone. It is noteworthy that the platinum-resistant cancer cells (A2780/CDDP) with the highest basal level of DJ-1 protein are most susceptible to the developed therapy and this susceptibility declines with decreasing basal levels of DJ-1. Finally, we interrogate the molecular underpinnings of the DJ-1 knockdown effects in the treatment of the ovarian cancer cells. By using various experimental techniques, it was revealed that DJ-1 depletion (1) decreases the activity of the Akt pathway, thereby reducing cellular proliferation and migration and increasing the antiproliferative effect of cisplatin on ovarian cancer cells; (2) enhances the activity of p53 tumor suppressor protein therefore restoring cell cycle arrest functionality and upregulating the Bax-caspase pathway, triggering cell death; and (3) weakens the cellular defense mechanisms against inherited oxidative stress thereby increasing toxic intracellular radicals and amplifying the reactive oxygen species created by the administration of cisplatin.
机译:我们报告了一种基于siRNA介导的多功能DJ-1蛋白抑制作用的铂抗性卵巢癌的有效治疗方式,该蛋白负责多种癌症的增殖,生长,侵袭,氧化应激和整体存活。制定的治疗策略可以单独使用,也可以与低剂量的一线化疗药物顺铂协同工作,以引起最大的治疗反应。为了实现有效的DJ-1抑制,我们构建了以聚丙烯亚胺树状大分子为基础的纳米平台,该平台靶向在卵巢癌细胞上过表达的LHRH受体。定量PCR和Western免疫印迹分析表明,在各种卵巢癌细胞中,递送的DJ-1 siRNA下调了靶向mRNA和相应蛋白质的表达,幅度超过80%。进一步证明,siRNA介导的DJ-1抑制作用显着损害所用卵巢癌细胞的增殖,生存力和迁移。最后,组合方法在所有研究的细胞系中均产生最明显的治疗反应,胜过单独的siRNA介导的DJ-1敲除和顺铂治疗。值得注意的是,DJ-1蛋白基础水平最高的铂类抗性癌细胞(A2780 / CDDP)最容易受到发达疗法的影响,并且随着DJ-1基础水平的降低,这种敏感性降低。最后,我们研究了DJ-1敲低效应在卵巢癌细胞治疗中的分子基础。通过使用各种实验技术,发现DJ-1耗竭(1)降低了Akt通路的活性,从而减少了细胞的增殖和迁移,并增加了顺铂对卵巢癌细胞的抗增殖作用; (2)增强p53肿瘤抑制蛋白的活性,从而恢复细胞周期阻滞功能并上调Bax-半胱天冬酶途径,触发细胞死亡; (3)减弱了针对遗传性氧化应激的细胞防御机制,从而增加了毒性细胞内自由基并放大了顺铂给药产生的活性氧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号